Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brunswick Corporation (BC) vs TransMedics Group Inc (TMDX) Price & Performance

Brunswick CorporationTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Brunswick Corporation vs TransMedics Group Inc — how do they compare? Brunswick Corporation trades at $81.32 (market cap $5.28B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Brunswick Corporation is the larger of the two by market cap, and Brunswick Corporation pays a 2.16% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

BCTMDX
Market Cap
$5.28B$3.10B
Sector
Consumer CyclicalTechnology
52-Week High
$89.22$150.42
52-Week Low
$58.75$61.99
Enterprise Value
$7.28B$3.49B
Dividend Yield
2.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brunswick Corporation

Brunswick Corporation (BC) trades at $80.27, down 0.2% on the day, with strong analyst support showing 71% buy ratings and an $85.33 consensus price target. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company remains unprofitable with negative net margins. Technical indicators show a bullish trend with current price near pivot point support at $81, while fundamentals reveal mixed performance with solid revenue but profitability challenges.

The outlook remains cautiously optimistic given strong institutional interest and recent earnings beats, but investors face risks from persistent negative profitability and high P/E valuation. Upside potential exists if the company can translate revenue stability into sustained earnings growth, though margin pressures and competitive threats warrant careful monitoring.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About Brunswick Corporation

Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines

Read more on BC

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX